Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: An evidence-based comparison

被引:67
作者
Ilag, Liza L. [1 ]
Kerr, Lisa [1 ]
Malone, James K. [1 ]
Tan, Meng H. [1 ]
机构
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
关键词
premixed insulin analogue; lispro; aspart; glargine; type; 2; diabetes;
D O I
10.1016/j.clinthera.2007.07.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Insulin is an effective treatment for type 2 diabetes (T2D)), a progressive condition in which insulin deficiency is one of the core defects. When patients with T2D) are unable to achieve glycemic goals with diet and oral antihyperglycerruic medications, a common starting insulin regimen consists of basal or premixed insulin added to oral antihyperglycemic medications. When glycemic goals are not achieved with the initial insulin regimen, a basal-bolus regimen is necessary. Objective: This article reviews clinical-trial data on the efficacy and safety profile of prandial premixed insulin analogues (insulin aspart and insulin lispro) compared with basal insulin analogues (insulin glargine, insulin detemir, and insulin lispro protamine suspension), with or without a prandial insulin analogue, in the management of T2D). Methods: A systematic search of Ovid, MEDLINE, and EMBASE (1995-2007) was performed to identify published randomized controlled trials comparing prandial premixed insulin analogues with basal insulin analogues, with or without prandial insulin, in patients with T2D). The search terms were premixed insulin analogues, premixed insulin, bipbasic insulin aspart, insulin aspart 70/30, insulin aspart 50150, premixed insulin lispro, insulin lispro 75125, insulin lispro 50150, glargine, and detemir. Abstracts presented at the 2005 and 2006 meetings of the American Diabetes Association and the European Association for the Study of Diabetes and bibliographies of the identified studies were also reviewed. Predetermined criteria for study inclusion were treatment duration of at least 12 weeks, T2D) diagnosed using valid criteria, use of a basal insulin analogue (with or without rapid-acting insulin) as a study comparator, and use of well-accepted end points (eg, glycosylated hemoglobin [HbA(1c)], hypoglycemia, preprandial and postprandial blood glucose). Results: Of the identified randomized controlled trials, 3 studies compared premixed insulin analogues containing 70 % or 75 % basal and 3 0 % or 25 % rapidacting insulin analogue with basal insulin analogues only, and 3 studies evaluated premixed insulin analogues containing 50% basal and 50% rapid-acting insulin analogue with basal insulin analogues only. Use of prandial premixed insulin analogues was associated with better overall and postprandial glycemic control. In the studies that compared twice-daily premixed insulin analogues with a basal insulin analogue, changes in HbA(1c) ranged from -1.00% to -2.79% and from -0.42% to -2.36%, respectively (P < 0.01). In the studies that compared thrice-daily premixed insulin analogues with a basal insulin analogue, changes in HbA(1c). ranged from -0.72% to -1.2% and from -0.3% to -0.75%, respectively (P < 0.01). These results were achieved with some increase in overall hypoglycemia, but not in nocturnal or severe hypoglycemia. Doses of the premixed insulin analogues were adjusted during the titration period to achieve glycemic goals. Conclusions: The results of this systematic review suggest that regimens consisting of prandial premixed insulin analogues, which provide both basal and prandial insulin coverage, may be used as an initial insulin regimen in patients with T2D to enable better overall, preprandial, and postprandial glycemic control compared with a basal insulin analogue regimen alone. Premixed insulin analogues are an effective option for initiating and intensifying insulin therapy in patients with T2D). (Clin Ther. 2007;29(Theme Issue):12541270) Copyright (c) 2007 Excerpta Medica, Inc.
引用
收藏
页码:1254 / 1270
页数:17
相关论文
共 57 条
[1]  
*AACE, 2002, ENDOCR PRACT S1, V8, P43
[2]  
[Anonymous], 2007, DIABETES CARE, DOI DOI 10.2337/DC07-S004
[3]  
[Anonymous], CAN J DIABETES
[4]   Achieving glycemic goals in type 2 diabetes [J].
Bloomgarden, Zachary T. .
DIABETES CARE, 2007, 30 (01) :174-180
[5]   Starting insulin therapy in type 2 diabetic patients - Does it really matter how? [J].
Davidson, MB .
DIABETES CARE, 2005, 28 (02) :494-495
[6]   Improvement of glycemic control in subjects with poorly controlled type 2 diabetes - Comparison of two treatment algorithms using insulin glargine [J].
Davies, M ;
Storms, F ;
Shutler, S ;
Bianchi-Biscay, M ;
Gomis, R .
DIABETES CARE, 2005, 28 (06) :1282-1288
[7]   Outpatient insulin therapy in type 1 and type 2 diabetes mellitus - Scientific review [J].
DeWitt, DE ;
Hirsch, IB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (17) :2254-2264
[8]   Comparison of thrice daily 'high' vs. 'medium' premixed insulin aspart with respect to evening and overnight glycaemic control in patients with type 2 diabetes [J].
Ejskjaer, N ;
Rasmussen, M ;
Kamp, N ;
Lindholm, A ;
Christiansen, JS .
DIABETES OBESITY & METABOLISM, 2003, 5 (06) :438-445
[9]   Postchallenge hyperglycemia in a national sample of US adults with type 2 diabetes [J].
Erlinger, TP ;
Brancati, FL .
DIABETES CARE, 2001, 24 (10) :1734-1738
[10]  
Farmer AJ, 2006, DIABETES, V55, pA474